Current ME Pb collimator configurations are probably not optimal for Lu-177, which is an isotope that is increasingly used for therapy of neuroendocrine tumors with Lutetium Lu 177 dotatate that binds to somatostatin receptors on tumors and metastasized prostate cancer using a prostate-specific membrane antigen (PSMA) labeled to Lu-177. Here, FOLH1 is linked to neuroendocrine neoplasm.